Assessment of measurable residual disease after induction chemotherapy in acute lymphoblastic leukemia patients in a tertiary care hospital
DOI:
https://doi.org/10.18203/2349-3933.ijam20242303Keywords:
Acute lymphoblastic leukemia, Measurable residual disease, Induction chemotherapy, Clinical outcomes, Biochemical markersAbstract
Background: Measurable residual disease (MRD) is a crucial prognostic factor in acute lymphoblastic leukemia (ALL), influencing treatment outcomes and long-term survival. This study investigates the prevalence of MRD post-induction chemotherapy and its association with clinical, demographic, and biochemical markers in ALL patients at a tertiary care hospital.
Methods: This observational cross-sectional study was conducted at Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, from August 2021 to July 2022. A total of 22 newly diagnosed ALL patients underwent induction chemotherapy and MRD evaluation using flow cytometry. Clinical signs, demographic data, and laboratory findings, including serum creatinine, uric acid, and BCR-ABL1 status, were recorded. Statistical analyses assessed the relationships between MRD status and various predictors.
Results: Of the 22 patients, 7 (31.82%) remained MRD positive after induction chemotherapy. Anaemia was prevalent, affecting 20 participants (90.91%). MRD positive patients had higher serum creatinine (mean 1.23±0.31 mg/dl) and uric acid levels (mean 7.09±1.62 mg/dl) compared to MRD negative patients. None of the MRD positive patients tested positive for BCR-ABL1. Six of the 7 MRD positive patients were male (85.71%). Bone marrow analysis showed 5 MRD positive patients (71.43%) achieved complete remission. Risk stratification did not significantly correlate with MRD status.
Conclusions: MRD is a critical prognostic tool in ALL management, correlating with higher biochemical markers of tumor burden and a distinct clinical profile. These findings support integrating MRD assessment with detailed clinical and laboratory evaluations to refine treatment strategies and improve patient outcomes in ALL.
References
Pui CH. Acute lymphoblastic leukemia in children. Curr Opin Oncol. 2000;12(1):3.
Bhojwani D, Yang JJ, Pui CH. Biology of Childhood Acute Lymphoblastic Leukemia. Pediatr Clin North Am. 2015;62(1):47-60.
Varghese B, Joobomary A, Savida P. Five-Year Survival Rate and the Factors for Risk-Directed Therapy in Acute Lymphoblastic Leukemia. Indian J Med Paediatr Oncol. 2018;39:301.
Abboud M, Ghanem K, Muwakkit S. Acute lymphoblastic leukemia in low and middle-income countries. Curr Opin Oncol. 2014;26.
Arora RS, Arora B. Acute leukemia in children: A review of the current Indian data. South Asian J Cancer. 2016;5(3):155-60.
Akabane H, Logan A. Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia. Clin Adv Hematol Oncol. 2020;18(7):413-22.
Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children’s Oncology Group study AALL0232. Blood. 2015;126(8):964-71.
Chen X, Wood BL. Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. Blood Rev. 2017;31(2):63-75.
Abou Dalle I, Jabbour E, Short NJ. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Ther Adv Hematol. 2020;11:2040620720910023.
Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia. JAMA Oncol. 2017;3(7):e170580.
Brown PA, Wieduwilt M, Logan A, DeAngelo DJ, Wang ES, Fathi A, et al. Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019. J Natl Compr Canc Netw. 2019;17(5):414-23.
Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C; ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):v69-82.
Tembhare PR, Narula G, Khanka T, Ghogale S, Chatterjee G, Patkar NV, et al. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients. Front Oncol. 2020;10.
Wiciński M, Liczner G, Cadelski K, Kołnierzak T, Nowaczewska M, Malinowski B. Anemia of Chronic Diseases: Wider Diagnostics—Better Treatment? Nutrients. 2020;12(6):1784.
Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6(12):1890-9.
Al-Daghri NM, Al-Attas OS, Wani K, Sabico S, Alokail MS. Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Saudi Type 2 Diabetic Patients. Sci Rep. 2017;7:12104.
Ephraim RKD, Awuku YA, Numekevor P, Botchway F, Adoba P, Dadzie EK, et al. Serum Uric acid is a better indicator of kidney impairment than serum uric acid to creatine ratio ; a cross sectional study of type 2 diabetes mellitus patients. J Diabetes Metab Disord. 2021;20(1):313-20.
Gupta S, Devidas M, Chen S, Wang C, Loh ML, Raetz E, et al. Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group (COG). Blood. 2016;128(22):758.
Zuna J, Moericke A, Arens M, Koehler R, Panzer-Grümayer R, Bartram CR, et al. Implications of delayed bone marrow aspirations at the end of treatment induction for risk stratification and outcome in children with acute lymphoblastic leukaemia. Br J Haematol. 2016;173(5):742-8.
Boscaro E, Urbino I, Catania FM, Arrigo G, Secreto C, Olivi M, et al. Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors. Cancers. 2023;15(13):3512.
